Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcellona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:4City/State/Province:Barcellona
Treatments:Biologic therapyHospital:Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona
Drugs:Journal:Link
Date:Jul 2008

Description:

Patients: This phase 3 study involved 602 patients with advanced hepatocellular carcinoma (liver cancer). The majority of patients (87%) were men.

Treatment: Patients were treated with Sorafenib or placebo (an inactive agent that looks like and is taken the same was as the active drug). Sorafenib is a biological therapy.

Toxicities: Grade 4 fatigue and bleeding were reported. Grade 3 fatigue, weight loss, hand-foot skin reaction, rash, diarrhea, nausea, vomiting, hypertension, liver dysfunction, abdominal pain, and bleeding were reported (in 8% or fewer patients).

Results: The median overall survival was 10.7 months for patients treated with sorafenib and 7.9 months for those given the placebo.

Support: This study was supported by research funds from Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals. Bayer markets sorafenib as Nexavar“

Correspondence: Dr. Josep M. Llovet or Dr. Jordi Bruix





Back